Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / TNYA - Gene therapy focused Tenaya Therapeutics down 13%

TNYA - Gene therapy focused Tenaya Therapeutics down 13%

Tenaya Therapeutics Inc.
Tenaya Therapeutics (TNYA -13.0%), which has several gene therapy candidates in preclinical development, is down ssignificantly today. As of 119p, volume was ~40.8K shares. Average daily volume is ~137.1K shares. Last month, Zacks Investment Research upgraded shares from sell to hold. One of its lead programs, TN-201, is an adeno-associated virus ("AAV") based gene therapy for several rare heart conditions. The company plans on filing an IND for the candidate in genetic hypotrophic cardiomyopathy next year. Another lead program, TYA-11631, is a small molecule precision medicine slated for an IND filing for heart failure with preserved ejection fraction and genetic dilated cardiomyopathy in 2022. For more on Tenaya, check out this background article from Avisol Capital Partners.

For further details see:

Gene therapy focused Tenaya Therapeutics down 13%
Stock Information
Company Name: Tenaya Therapeutics Inc.
Stock Symbol: TNYA
Market: NASDAQ
Website: tenayatherapeutics.com
Menu
TNYA TNYA Quote TNYA Short TNYA News TNYA Articles TNYA Message Board
Get TNYA Alerts

News, Short Squeeze, Breakout and More Instantly...